Publicly Funded

Immunization Schedules
for Ontario
June 2022
 programs and vaccine intervals (minimum and
What is this resource? recommended) for vaccine series.
The vaccine interval information is used
This document outlines the Publicly when individuals are ‘off-schedule’ with their
Funded Immunization Schedules for recommended vaccines.
Ontario as of June 2022. The minimum age and interval is the shortest
This document is intended primarily for health time between two vaccine doses in a series in
care providers who administer immunizations. which a protective response can be expected.
It is to be used as a reference tool for immunizers, However, it is preferable to maintain the
and provides information regarding: recommended age and interval when possible
as this will provide optimal protection or has the
1. The routine immunization schedule
best evidence of efficacy.
2. Catch-up immunization schedules This document also includes timing information on
3. High risk immunization programs how to complete the Pneu-C-13 series, as well as
and schedules the Tdap-IPV series depending on an individual’s
current age and previous doses received.
4. Eligibility criteria for all publicly funded Remove any previous versions of this document from your clinic areas
and refer only to this version to ensure up-to-date information.
vaccines and
5. Minimum and recommended intervals COVID-19 vaccine
between doses for vaccine series.
This resource does not include recommended
How to use this schedules for COVID-19 immunizations.
Please refer to the latest guidance for COVID-19
document: vaccination at: health.gov.on.ca/en/pro/
programs/publichealth/coronavirus/2019_
Pages three to five of this document are guidance.aspx
Ontario’s routine and catch-up immunization
schedules. The schedules are small images and
may be difficult to read. For a larger version of Immunizers should take responsibility
the schedules, visit health.gov.on.ca/en/pro/ for ensuring they have up-to-date
programs/immunization/schedule.aspx where knowledge using appropriate guidelines
they are available as a PDF file for download. and resources such as vaccine product
This document will need to be printed and each monographs and the Canadian
of the schedules will need to be assembled to
Immunization Guide (CIG)
make an easy-to-read resource.
(canada.ca/en/public-health/services/
The larger-print assembled schedules can canadian-immunization-guide.html).
be posted or kept with a printed copy of
this document for easy reference in your Immunizers with questions on the
immunization areas. Publicly Funded Immunization
Schedules for Ontario can contact their
The remainder of this document contains
local public health unit
information regarding eligibility for all
publicly funded vaccines as well as high risk (see pages 14-15 for contact information).

2 Print/view this document at: health.gov.on.ca/en/pro/programs/immunization/schedule.aspx

3
Publicly Funded Immunization Schedules for Ontario – June 2022
Publicly funded vaccines may be provided only to eligible individuals and must be free of charge
Routine Schedule: Children Starting Immunization in Infancy

Age 2 4 6 1 15 18 4 Grade 14 24 ≥34 65

Vaccine Months Months Months Year Ф Months Months Years 7 Years Years Years Years

DTaP-IPV-Hib
Diphtheria, Tetanus, Pertussis, Polio, ◆ ◆ ◆ ◆
Haemophilus influenzae type b

Pneu-C-13
Pneumococcal Conjugate 13 ◆ ◆ ◆
Rot-1
Rotavirus ▲ ▲

Men-C-C
Meningococcal Conjugate C ◆
MMR ■
Measles, Mumps, Rubella

Var ■
Varicella

Publicly Funded Immunization Schedules for Ontario – June 2022

MMRV ■
Measles, Mumps, Rubella, Varicella

Tdap-IPV
Tetanus, diphtheria, pertussis, Polio ◆
HB ●
Hepatitis B

Men-C-ACYW ●
Meningococcal Conjugate ACYW-135

HPV-9 ●
Human Papillomavirus

Tdap
Tetanus, diphtheria, pertussis ◆ ◆

Td (booster) ◆
Tetanus, diphtheria Every 10
years

HZ
Herpes Zoster ❙
Pneu-P-23
Pneumococcal Polysaccharide 23 ■/

Tdap ◆ One dose in every pregnancy, ideally between 27-32 weeks

Tetanus, diphtheria, pertussis of gestation
Inf Every year in the fall ✶
Influenza
◆ - A single vaccine dose given by intramuscular injection - Once a dose of Tdap is given in adulthood (24 years of age), adults should receive
Td boosters every 10 years thereafter
■ - A single vaccine dose given by subcutaneous injection
▲ - A single vaccine dose given by mouth
❙ - HZ is a 2 dose series (see Table 12) given by intramuscular injection

● - Provided through school-based immunization programs. Men-C-ACYW is a single dose; HB is a

✶ - Children 6 months to 8 years of age who have not previously received a dose of influenza
2 dose series (see Table 6); HPV-9 is a 2 dose series (see Table 10). Each vaccine dose is given vaccine require 2 doses given ≥4 weeks apart. Children who have previously received ≥1 dose
by intramuscular injection of influenza vaccine should receive 1 dose per season thereafter
Ф - Given no earlier than the 1st birthday, and prior to 16 months of age Note: A different schedule and/or additional doses may be needed for high risk individuals
(see Table 3) or if doses of a vaccine series are missed (see appropriate Tables 4-24)
4
Publicly Funded Immunization Schedules for Ontario – June 2022
Publicly funded vaccines may be provided only to eligible individuals and must be free of charge
Catch-up Schedule 1: Children Starting Immunization between 1-6 Years

3rd Visit: 4th Visit:

1st Visit: 2nd Visit: 24-28
2 months after 1st visit 2 months 6-12 months 5th Visit yrs
after 2nd visit after 3rd visit (only required
Age if child was
If child is <5 years and <4 years
If child is was If child is If child is If child is Grade 14-18 If adult was ≥34 65
at 4th visit): 7 yrs§ yrs yrs
4-6 yrs of age
Vaccine 2-3 and <18 yrs ≥18 yrs
<2 yrs 4 yrs 6-12 months
<4 4 5-6 yrs 5-6 7 <7 7 <4 4-8 at at
at 1st at 1st after 4th visit
yrs yrs yrs at 1st yrs yrs yrs yrs yrs yrs previous previous
visit visit
visit visit † visit

DTaP-IPV-Hib ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆
Pneu-C-13 ◆ ◆ ◆
MMR ■

MMRV ■ ■ ■ ■

Var ■ ■

Men-C-C ◆ ◆ ◆
Tdap-IPV ◆ ◆ ◆ ◆
HB ●

Men-C-ACYW ●

HPV-9 ●

Tdap ◆ ◆
◆
Td ◆ Every
10
years

HZ ❙
Pneu-P-23 ■ /◆
◆ One dose in every pregnancy, ideally between
Tdap 27-32 weeks of gestation

Inf Every year in the fall ✶

◆ - A single vaccine dose given by intramuscular injection - Once a dose of Tdap is given in adulthood (>18 yrs), adults should receive Td boosters every 10 years
■ - A single vaccine dose given by subcutaneous injection thereafter
● - Provided through school-based immunization programs. Men-C-ACYW is a single dose; ❙ - HZ is a 2 dose series (see Table 12) given by intramuscular injection
HB is a 2 dose series (see Table 6); HPV-9 is a 2 dose series (see Table 10). ✶ - Children 6 months to 8 years of age who have not previously received a dose of influenza vaccine require
Each vaccine dose is given by intramuscular injection 2 doses given ≥4 weeks apart. Children who have previously received ≥1 dose of influenza vaccine should
§ - Given 10 years after the (4-8 year old) Tdap-IPV dose receive 1 dose per season thereafter
† - Given 10 years after the adolescent Tdap dose Note: A different schedule and/or additional doses may be needed for high risk individuals (see Table 3) or
if doses of a vaccine series are missed (see appropriate Tables 4-24)
5
Publicly Funded Immunization Schedules for Ontario – June 2022
Publicly funded vaccines may be provided only to eligible individuals and must be free of charge
Catch-up Schedule 2: Children Starting Immunization between 7–17 Years
1st Visit 2nd Visit: 2 months after 1st Visit 10 years after
Age 3rd Visit: previous visit Every 10
Grades 10 Years
6-12 months 7-12 after 3rd Visit (only required if years after the 65 Years
Vaccine If child is If child is If child is If child is after 2nd Visit child was <18 yrs old previous visit
<13 yrs 13 to 17 yrs <13 yrs 13 to 18 yrs at previous visit)
Tdap-IPV ◆ ◆ ◆ ◆ ◆
MMRV ■ ■
MMR ■ ■
Var ■ ■
Men-C-C ◗
HB ●
Men-C-ACYW ●
HPV-9 ●
Tdap ◆ ◆
Td ◆
HZ ❙
Pneu-P-23 ■/
Tdap ◆ One dose in every pregnancy, ideally between 27-32 weeks of gestation

Publicly Funded Immunization Schedules for Ontario – June 2022

Inf Every year in the fall ✶

◆ - A single vaccine dose given by intramuscular injection - Once a dose of Tdap is given in adulthood, adults should receive Td boosters every 10 years thereafter
■ - A single vaccine dose given by subcutaneous injection ❙ - HZ is a 2 dose series (see Table 12) given by intramuscular injection
◗ - Individuals born on or after 2003/Sept/01 are eligible to receive a dose of Men-C-C (given by intramuscular injection). These ✶ - Children 6 months to 8 years of age who have not previously received a dose of influenza vaccine require
individuals are also eligible to receive Men-C-ACYW when they enter Grade 7. If the individual 2 doses given ≥4 weeks apart. Children who have previously received ≥1 dose of influenza vaccine should
is immunized with Men-C-ACYW, in or after Grade 7, Men-C-C is no longer recommended receive 1 dose per season thereafter
● - Provided through school-based immunization programs. Men-C-ACYW is a single dose; HB is a 2 dose Note: A different schedule and/or additional doses may be needed for high risk individuals
series (see Table 6); HPV-9 is a 2 or 3 dose series (see Tables 10 and 11). Each vaccine dose is given by intramuscular injection (see Table 3) or if doses of a vaccine series are missed (see appropriate Tables 4-24)

Catch-up Schedule 3: Adults Starting Immunization at 18 Years and Older

st
1 Visit 2nd Visit: 2 months after 1st Visit
Age If adult is born If adult is born 3rd Visit: Every 10 years
6-12 months after the 65 Years
Vaccine in or prior to between between in or after 2000 in or prior to 1999 in or prior to 1999 after 2nd Visit 3rd Visit
in or after 2000
1985 1986 and 1996 1997 and 1999 and is 18 to 25 yrs and is 20 to 25 yrs and is ≥26 yrs

Tdap-IPV ◆ ◆ ◆ ◆
MMR ■ ■ ■ ■ ■ ■
Var ■ ■
Men-C-ACYW ◆ ◆
Men-C-C ◆
Td ◆ ◆ ◆ ◆ ◆
IPV ■ ■ ■ ■
HZ ❙
Pneu-P-23 ■/
Tdap ◆ One dose in every pregnancy, ideally between 27-32 weeks of gestation
Inf Every year in the fall ◆

◆ - A single vaccine dose given in a syringe and needle by intramuscular injection ❙ - HZ is a 2 dose series (see Table 12) given by intramuscular injection
■ - A single vaccine dose given in a syringe and needle by subcutaneous injection Note: A different schedule and/or additional doses may be needed for high risk individuals (see Table 3) or if doses of a vaccine series are missed
(see appropriate Tables 4-24)
Table 1: Vaccine Administration
Age and weight (if applicable) of Preferred Site of
Route of administration Needle Gauge Needle Length
vaccine recipient Injection

Intramuscular (IM) 90 º angle 6 to 12 months Anterolateral thigh 22-25 ⅞” – 1”

Note: For IM injections, use 13 months to 12 years Deltoid muscle 22-25 ⅝” – 1”
a needle length sufficient to
reach the largest part of the
muscle Individuals weighing
Deltoid muscle 22-25 ⅝” – 1”
<130 lbs

Males weighing 130-260 lbs Deltoid muscle 22-25 1”

≥13 years Females weighing 130-200 lbs Deltoid muscle 22-25 1”

Males weighing >260 lbs Deltoid muscle 22-25 1½”

Females weighing >200 lbs Deltoid muscle 22-25 1½”

Subcutaneous (SC) 45 º <1 year Anterolateral thigh
angle
Upper triceps area or 25 ⅝”
≥1 year anterolateral thigh
Oral (PO) Infants n/a
Intranasal (IN) All ages n/a
Notes: • For route, site and technique for vaccine administration refer to the Canadian Immunization Guide at canada.ca/en/public-health/servic-
es/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/
page-8-vaccine-administration-practices.html
• Never mix and administer different vaccines together in the same syringe unless indicated in the product monograph
• For vaccines that require reconstitution, always mix the vaccine with supplied diluent for that vaccine

Table 2: Eligibility Criteria for All Publicly Funded Vaccines

Route of Publicly Funded Age Groups
Publicly Funded Vaccines
administration Routine Vaccine Programs High Risk Vaccine Programs
DTaP-IPV-Hib
Diphtheria, Tetanus, Pertussis, Polio, IM 6 weeks to 6 years of age 5 to 6 years of age (see Table 3)
Haemophilus influenzae type b
HA
Hepatitis A
IM ≥1 year of age (see Table 3)
HB
Hepatitis B
IM Grades 7 to 12 ≥0 years of age (see Table 3)
Hib
Haemophilus influenzae type b
IM 6 weeks to 4 years of age ≥5 years of age (see Table 3)
65 to 70 years of age
HZ
IM Note: 2 dose series should be
Herpes Zoster
completed prior to 71st birthday
HPV-9
IM Grades 7 to 12 Males 9 to 26 years of age (see Table 3)
Human Papillomavirus
Inf
Influenza
IM ≥6 months of age
IPV
Polio
SC ≥6 weeks of age ≥18 years of age (see Table 3)
4CMenB
IM 2 months to 17 years of age (see Table 3)
Multicomponent Meningococcal B
• Born on or after 2003/Sep/01
Men-C-C
IM and ≥1 year of age
Meningococcal Conjugate C
• Born between 1986 and 1996
Men-C-ACYW • Grades 7 to 12
Meningococcal Conjugate ACYW-135
IM
• Born in or after 1997 ≥9 months of age (see Table 3)
MMR • 6 to 11 months (see Table 3)
Measles, Mumps, Rubella
SC ≥1 year of age • ≥26 years of age (see Table 3)

6
 Table 2 cont.: Eligibility Criteria for All Publicly Funded Vaccines
Route of Publicly Funded Age Groups
Publicly Funded Vaccines
administration Routine Vaccine Programs High Risk Vaccine Programs
MMRV
SC 4 to 12 years of age
Measles, Mumps, Rubella, Varicella
Pneu-C-13 • 6 weeks to 6 months of age (see Table 3)
IM 6 weeks to 4 years of age
Pneumococcal Conjugate 13 • ≥50 years of age (see Table 3)
Pneu-P-23 • 2 to 64 years of age (see Table 3)
Pneumococcal Polysaccharide 23
SC or IM ≥65 years of age • ≥2 years of age (reimmunization) (see Table 3)
Rot-1
PO 6 to 24 weeks of age
Rotavirus
Td
Tetanus, diphtheria
IM ≥7 years of age
• ≥4 years of age
• Pregnant persons in every
pregnancy, regardless of Tdap
immunization history
Note: adults (≥18 years of age) are
eligible for 1 Tdap dose
Tdap (generally given 10 years after the
IM
Tetanus, diphtheria, pertussis adolescent Tdap dose).
However, if the Tdap booster dose
is required earlier, they are eligible
to receive 1 dose of Tdap regardless
of the interval since the last dose of
tetanus- or diphtheria-containing
vaccine.
Tdap-IPV
Tetanus, diphtheria, pertussis, Polio
IM ≥4 years of age ≥18 years of age (see Table 3)
Var Born in or after 2000
SC and ≥1 year of age Born in or prior to 1999 (see Table 3)
Varicella
Notes: • Some vaccines protect against the same disease; the most appropriate vaccine should be selected based on the age and needs of the vaccine recipient in
accordance with the recommended schedules
• For any of the immunization schedules, if an individual is partially immunized or contraindicated to receive a component of a combined vaccine, alternative
vaccines may be used, provided the individual is eligible to receive the vaccine, for example:
• If IPV series is complete Tdap can be used instead of Tdap-IPV
• Similarly, if there is a contraindication to receiving pertussis, Td and IPV for individuals ≥7 years of age can be used instead of Tdap-IPV

Consult with your local public health unit regarding the availability of publicly funded vaccines for the case and contact management of vaccine preventable diseases.

Table 3: High Risk Vaccine Programs

High risk individuals should also be immunized according to the routine or applicable catch-up schedules (see pages 3 to 5)

Publicly
Publicly Funded # of Eligible Vaccine
Funded High Risk Eligibility Criteria
Vaccines Doses Intervals
Age Groups
• Asplenia (functional or anatomic) (1 dose)
Hib ≥5 years • Bone marrow or solid organ transplant recipients (1 dose)
• Cochlear implant recipients (pre/post implant) (1 dose)
For HSCT - • Hematopoietic stem cell transplant (HSCT) recipients (3 doses)
1 or 3 See • Immunocompromised individuals related to disease or therapy (1 dose)
Table 9 • Lung transplant recipients (1 dose)
DTaP-IPV-Hib 5-6 years • Primary antibody deficiencies (1 dose)
Note: High risk children 5 to 6 years of age who require DTaP-IPV and Hib should receive
DTaP-IPV-Hib instead of Hib
• Intravenous drug use
See
HA ≥1 year 2
Table 5
• Liver disease (chronic), including hepatitis B and C
• Men who have sex with men

• Children <7 years old whose families have immigrated from countries of high prevalence for HBV
and who may be exposed to HBV carriers through their extended families (3 doses)
• Household and sexual contacts of chronic carriers and acute cases (3 doses)
• History of a sexually transmitted disease (3 doses)
• Infants born to HBV-positive carrier mothers:
- premature infants weighing <2,000 grams at birth (4 doses)
2 to 4 - premature infants weighing ≥2,000 grams at birth and full/post term infants (3 doses)
See
HB ≥0 years (+ boosters
Table 7
• Intravenous drug use (3 doses)
if required) • Liver disease (chronic), including hepatitis C (3 doses)
• Awaiting liver transplants (2nd and 3rd doses only)
• Men who have sex with men (3 doses)
• Multiple sex partners (3 doses)
• Needle stick injuries in a non-health care setting (3 doses)
7 Publicly Funded Immunization Schedules for Ontario – June 2022 • On renal dialysis or those with diseases requiring frequent receipt of blood products
(e.g., haemophilia) (2nd and 3rd doses only)
Table 3 cont.: High Risk Vaccine Programs
High risk individuals should also be immunized according to the routine or applicable catch-up schedules (see pages 3 to 5)

Publicly
Publicly Funded # of Eligible Vaccine
Funded High Risk Eligibility Criteria
Vaccines Doses Intervals
Age Groups
Males 9 to See Tables
HPV-9 2 to 3 10 and 11
• Men who have sex with men
26 years
2 months to See
4CMenB 2 to 4 Table 14 • Acquired complement deficiencies (e.g., receiving eculizumab)
17 years
• Asplenia (functional or anatomic)
9 months to 2 to 4 See • Cochlear implant recipients (pre/post implant)
Men-C-ACYW
55 years + boosters Table 15 • Complement, properdin, factor D or primary antibody deficiencies
See • HIV
Men-C-ACYW ≥56 years 1 Table 15
See • Infants traveling to areas/countries where disease is of concern
6-11 months 1
Table 16 Note: 2 additional doses are required at ≥1 year of age and at appropriate intervals
Adults who have only received 1 dose of MMR are eligible to receive a 2nd dose:
MMR • if they are health care workers
1 See
≥26 years (as a 2nd dose) Table 16
• if they are post-secondary students
• if they are planning to travel to areas where disease is of concern
• based on the health care provider’s clinical judgement
• Infants who meet any of the Pneu-P-23 high risk criteria from 1 to 14 (see Pneu-P-23
6 weeks to 1 See
eligibility criteria) are eligible for a 4th dose and should be immunized according to the high
6 months (as a 4th dose) Table 17 risk Pneu-C-13 schedule
• Asplenia (anatomical or functional) (1 dose)
For HSCT – • Congenital immunodeficiencies involving any part of the immune system, including B-lympho-
See Table cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-
18 din, or factor D deficiencies), or phagocytic functions (1 dose)
Pneu-C-13 • HIV (1 dose)
For intervals • HSCT recipient (3 doses)
≥50 years 1 or 3 between • Immunocompromising therapy including use of long-term corticosteroids, chemotherapy,
Pneu-C-13 radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic
and drugs (1 dose)
Pneu-P-23 – • Malignant neoplasms including leukemia and lymphoma (1 dose)
• Sickle cell disease or other hemoglobinopathies (1 dose)
See Table 19
• Solid organ or islet cell transplant (candidate or recipient) (1 dose)

• Asplenia (functional or anatomic), splenic dysfunction

• Cardiac disease (chronic)
• Cerebral spinal fluid leak (chronic)
• Cochlear implant recipients (pre/post implant)
• Congenital (primary) immunodeficiencies involving any part of the immune system, including
B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement
system (properdin, or factor D deficiencies), or phagocytic functions
• Diabetes mellitus
• HIV
• Immunocompromising therapy including use of long-term systemic corticosteroid,
chemotherapy, radiation therapy, post-organ transplant therapy, certain anti-rheumatic drugs
Pneu-P-23 2 to 64 years 1 and other immunosuppressive therapy
• Liver disease chronic, including hepatitis B and C, and hepatic cirrhosis due to any cause
• Malignant neoplasms, including leukemia and lymphoma
• Renal disease (chronic), including nephrotic syndrome
• Respiratory disease (chronic), excluding asthma, except those treated with high-dose
corticosteroid therapy
• Sickle-cell disease and other sickle cell haemoglobinopathies
• Solid organ or islet cell transplant (candidate or recipient)
• Neurologic conditions (chronic) that may impair clearance of oral secretions
• HSCT (candidate or recipient)
• Residents of nursing homes, homes for the aged and chronic care facilities or wards
Individuals are eligible to receive a 2nd (one lifetime reimmunization) dose of Pneu-P-23 if they
meet the following high risk criteria:
1 See • Asplenia (functional or anatomic) or sickle cell disease
Pneu-P-23 ≥2 years (as a 2nd dose) Table 20
• Hepatic cirrhosis
• HIV
• Immunocompromised related to disease or therapy
• Renal failure (chronic) or nephrotic syndrome

Travellers who have completed their immunization series against polio and are travelling
to areas where poliovirus is known or suspected to be circulating
IPV
Refer to the Committee to Advise on Tropical Medicine and Travel (CATMAT) for recommendations
Tdap-IPV ≥18 years 1 at phac-aspc.gc.ca/tmp-pmv/catmat-ccmtmv/index-eng.php
Note: Travellers are eligible to receive a single adult lifetime booster dose of IPV-containing vaccine.
The most appropriate vaccine (i.e., IPV or Tdap-IPV) should be selected
• Susceptible children and adolescents given chronic salicylic acid therapy
• Susceptible individuals with cystic fibrosis
Born in or prior See
Var 2 • Susceptible household contacts of immunocompromised individuals
to 1999 Table 16 • Susceptible individuals receiving low dose steroid therapy or inhaled/topical steroids
• Susceptible immunocompromised individuals, see the Canadian Immunization Guide

8
Vaccine Intervals – Recommended and Minimum
Note: Tables 8, 12, 13, 14, 15 and 17 should be used with initiating the vaccine series. Interrupted schedules may result in fewer necessary
doses than indicated in the table. Consult the Canadian Immunization Guide or Table 23 for the interrupted Pneu-C-13 series.

Table 4: DTaP-IPV-Hib and Tdap-IPV primary immunization series for children <7 years of age
Recommended Intervals Minimum Intervals
1st DTaP-IPV-Hib dose at age ≥2 months 1st DTaP-IPV-Hib dose at age ≥6 weeks
2nd DTaP-IPV-Hib dose, 2 months after 1st dose 2nd DTaP-IPV-Hib dose, 4 weeks after 1st dose
3rd DTaP-IPV-Hib dose, 2 months after 2nd dose 3rd DTaP-IPV-Hib dose, 4 weeks after 2nd dose
4th DTaP-IPV-Hib dose, 6-12 months after 3rd dose and age ≥1 year 4th DTaP-IPV-Hib dose, 24 weeks after 3rd dose and age ≥1 year
If 4th dose is given at age ≥4 years and ≥24 weeks after 3 rd dose, and If 4th dose is given at age ≥4 years and ≥24 weeks after 3rd dose,
3rd dose is given at age ≥1 year, Tdap-IPV should be given Tdap-IPV should be given
5th Tdap-IPV dose, 6-12 months after 4th dose and at age ≥4 years 5th Tdap-IPV dose, 24 weeks after 4th dose and at age ≥4 years
5 th dose is not required if 4th dose is given at age ≥4 years and 5 th dose is not required if 4th dose is given at age ≥4 years and
≥24 weeks after 3rd dose ≥24 weeks after 3rd dose
Note:
• Refer to the Routine Schedule and Catch-up Schedule 1 for the use of DTaP-IPV-Hib

Table 5: Hepatitis A (HA) immunization series for high risk individuals ≥1 year of age
Recommended Intervals Minimum Intervals
1st dose 1st dose
2nd dose, 6 to 36 months after 1st dose (depending on vaccine) 2nd dose, 24 weeks after 1st dose

Table 6: Hepatitis B (HB) immunization series for grade 7

Recombivax® HB First Dose – Intervals Engerix®-B First Dose - Intervals
1st dose Recombivax® HB in Grade 7 1st dose Engerix®-B in Grade 7
2nd dose Recombivax® HB or Engerix®-B, 4 months after 1st dose 2nd dose Engerix®-B or Recombivax® HB, 6 months after 1st dose
Note: The 2 dose HB schedule and vaccine formulation is licensed for use for children between 11 and 15 years of age.
For children who have not received their 2nd dose prior to their 16th birthday, a 3-dose series is required. Follow Table 7 for the 2nd and 3rd doses;
no need to restart the series

Table 7: Hepatitis B (HB) immunization series for high risk individuals ≥0 years of age and students in grades 10 to
12 who are ≥16 years of age
Recommended Intervals Minimum Intervals
1 dose
st
1 dose
st

2nd dose, 1 month after 1st dose 2nd dose, 4 weeks after 1st dose
3rd dose, 5 months after 2nd dose and at age ≥24 weeks 3rd dose, 8 weeks after 2nd dose, 16 weeks after 1st dose and at age ≥24 weeks

Notes:
• Premature infants weighing < 2,000 grams at birth, born to HBV-positive mothers, should receive 4 doses, given at birth, 1, 2 and 6 months of age
• Refer to the Canadian Immunization Guide for appropriate vaccine formulations, serology testing and boosters for individuals who meet HB high risk
eligibility criteria (see Table 3)

Table 8: type b (Hib) immunization series for children <5 years of age
Age at first dose Recommended Intervals Minimum Intervals
1 dose
st
1 dose
st

2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
2-6 months
3rd dose, 2 months after 2nd dose 3rd dose, 4 weeks after 2nd dose
4th dose, 2 months after 3rd and at age ≥12 months 4th dose, 8 weeks after 3rd dose and at age ≥12 months
1st dose 1st dose
7-11 months 2nd dose, 2 months after 1st dose 2nd dose, 8 weeks after 1st dose
3rd dose, 2 months after 2nd dose and at age ≥12 months 3rd dose, 8 weeks after 2nd dose and at age ≥12 months
1st dose 1st dose
12-14 months
2nd dose, 2 months after 1st dose 2nd dose, 8 weeks after 1st dose
15-59 months 1st dose 1st dose

9 Publicly Funded Immunization Schedules for Ontario – June 2022

Table 9: type b (Hib) immunization series for HSCT recipients ≥5 years of age
Recommended Intervals Minimum Intervals
1st dose 1st dose
2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
3rd dose, 12 months after 2nd dose 3rd dose, 4 weeks after 2nd dose
Note: Immunization series can be initiated at 6 to 12 months post-transplant

Table 10: HPV-9 two dose immunization series for:

• healthy grade 7 to 12 students who are <15 years of age
• healthy youth 9 to 14 years of age (who meet high risk eligibility criteria)

Recommended Intervals Minimum Intervals

1 dose
st
1 dose
st

2nd dose, 6 months after 1st dose 2nd dose, 24 weeks after 1st dose
Notes:
• Immunocompromised or immunocompetent HIV-infected individuals require 3 doses (see Table 11)
• In healthy individuals 15 years of age and older who received the first dose between 9 to less than 15 years of age, a 2 dose schedule can
be used

Table 11: HPV-9 three dose immunization series for:

Healthy:
• grade 7 to 12 students who are ≥15 years of age
• males 15 to 26 of age (who meet high risk eligibility criteria)
Immunocompromised or immunocompetent HIV-infected:
• grade 7 to 12 students
• males 9 to 26 years of age (who meet high risk eligibility criteria)

Recommended Intervals Minimum Intervals

1 dose
st
1 dose
st

2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
3rd dose, 4 months after 2nd dose 3rd dose, 12 weeks after 2nd dose and 24 weeks after the 1st dose

Table 12: HZ immunization series for individuals 65 to 70 years of age

Age at first dose Recommended Intervals Minimum Intervals
1 dose
st
1 dose
st
65 to 70 years
2nd dose, 2 to 6 months after 1st dose 2nd dose, 8 weeks after 1st dose

Table 13: IPV immunization series for individuals ≥6 weeks of age

Age at first dose Recommended Intervals Minimum Intervals
1 dose
st
1 dose
st

2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
6 weeks 3rd dose, 2 months after 2nd dose 3rd dose, 4 weeks after 2nd dose
to 3 years 4th dose, 6 to 12 months after 3rd dose 4th dose, 24 weeks after 3rd dose
4th dose is not required if 3 rd dose is given at age ≥4 4th dose is not required if 3 rd dose is given at age ≥4 years
years and ≥24 weeks after 2 nd dose and ≥24 weeks after 2 nd dose
1st dose 1st dose
≥4 years 2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
3rd dose, 6 to 12 months after 2nd dose 3rd dose, 24 weeks after 2nd dose

Table 14: 4CMenB immunization series for high risk children 2 months to 17 years of age
Age at first dose Recommended Intervals Minimum Intervals

1 dose
st
1 dose
st

2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
2-5 months
3rd dose, 2 months after 2nd dose 3rd dose, 4 weeks after 2nd dose
4th dose, 2 months after 3rd and at age ≥12 months 4th dose, 8 weeks after 3rd dose and at age ≥12 months

1st dose 1st dose

6-11 months 2nd dose, 2 months after 1st dose 2nd dose, 8 weeks after 1st dose
3rd dose, 2 months after 2nd dose and at age ≥12 months 3rd dose, 8 weeks after 2nd dose and at age ≥12 months

10
 Table 14 cont.: 4CMenB immunization series for high risk children 2 months to 17 years of age
Age at first dose Recommended Intervals Minimum Intervals
1 dose
st
1 dose
st
12 months to 10 years
2nd dose, 2 months after 1st dose 2nd dose, 8 weeks after 1st dose
1st dose 1st dose
11 to 17 years
2nd dose, 1 month after 1st dose 2nd dose, 4 weeks after 1st dose

Table 15: Men-C-ACYW immunization series for high risk individuals 9 months and older
Age at first dose Recommended Intervals Minimum Intervals
1st dose
1st dose
2nd dose, 4 weeks after 1st dose
2nd dose, 2 months after 1st dose
3rd dose, 4 weeks after 2nd dose
9 to 11 months 3rd dose, 2 months after 2nd dose
4th dose, 4 weeks after 3rd dose and at age ≥12 months
and at age ≥12 months
4 th dose is not required if 3rd dose is given at age ≥12 months and ≥4 weeks after 2 nd dose
Booster doses every 3 to 5 years
Booster doses every 3 to 5 years
1st dose 1st dose
12 months
2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
to 6 years
Booster doses every 3 to 5 years Booster doses every 3 to 5 years
1st dose 1st dose
7 to 55 years 2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
Booster doses every 5 years Booster doses every 5 years

• For high risk individuals ≥56 years of age, a single lifetime dose of Men-C-ACYW may be given ≥5 years after last dose of
56 years and older Men-C-ACYW
• Vaccines available and provided publicly funded for these individuals may not be included in the age indication for that
particular vaccine. Therefore, administration of these vaccines is off-label and clinical judgment is advised.
Notes:
• ≥4 weeks is required between doses of Men-C-ACYW and Men-C-C

Table 16: MMR, MMRV and Var immunization series

Order of Vaccines Recommended Intervals Minimum Intervals
MMR then MMR 1 month 4 weeks
MMR then MMRV / MMRV then MMR 3 months 6 weeks
MMR then Var / Var then MMR 1 month 4 weeks
MMRV then MMRV 3 months 6 weeks
Var then MMRV / MMRV then Var 3 months 6 weeks
Var then Var 3 months 6 weeks
Note: MMR and Var may be given at the same visit if required

Table 17: Pneu-C-13 immunization series for children <5 years of age
Age at first Applies
Recommended Intervals Minimum Intervals
dose to
1st dose at age ≥2 months 1st dose at age ≥6 weeks
Healthy 2nd dose, 2 months after 1st dose 2nd dose, 8* weeks after 1st dose
3rd dose, 2 months after 2nd dose and at age ≥12 months 3rd dose, 8 weeks after 2nd dose and at age ≥12 months
2-6 months 1st dose at age ≥2 months 1st dose at age ≥6 weeks
2nd dose, 2 months after 1st dose 2nd dose, 8* weeks after 1st dose
High risk
3rd dose, 2 months after 2nd dose 3rd dose, 8* weeks after 2nd dose
4th dose, 2 months after 3rd dose and at age ≥12 months 4th dose, 8 weeks after 3rd dose and at age ≥12 months
1st dose 1st dose
7-11 months All 2nd dose, 2 months after 1st dose 2nd dose, 8* weeks after 1st dose
3rd dose, 2 months after 2nd dose and at age ≥12 months 3rd dose, 8 weeks after 2nd dose and at age ≥12 months
1st dose 1st dose
12-23 months All
2nd dose, 2 months after 1st dose 2nd dose, 8 weeks after 1st dose
24-59 months All 1 dose 1 dose

* For these doses, the vaccine manufacturer indicates the minimum interval is 4 weeks, however the Canadian Immunization Guide recommends
the minimum interval between doses be 8 weeks
Note: 1 dose of Pneu-P-23 should be given ≥8 weeks after the last dose of Pneu-C-13, for children ≥2 years of age who meet Pneu-P-23 high risk
criteria (see Table 3)

11 Publicly Funded Immunization Schedules for Ontario – June 2022

 Table 18: Pneu-C-13 immunization series for HSCT recipients ≥50 years of age
Recommended Intervals Minimum Intervals
1st dose 1st dose
2nd dose, 1 month after 1st dose 2nd dose, 4 weeks after 1st dose
3rd dose, 1 month after 2nd dose 3rd dose, 4 weeks after 2nd dose

Note: Start series 3 to 9 months after transplant; 1 dose of Pneu-P-23 should be given 12 to 18 months post-transplant (6 to 12 months
after last dose of Pneu-C-13)

Table 19: Pneu-C-13 and Pneu-P-23 intervals for high risk adults ≥50 years of age
• 1 dose of Pneu-P-23 should be given ≥8 weeks after the last dose of Pneu-C-13 (except for HSCT recipients see Table 1 for intervals)
• Alternatively, if Pneu-P-23 has already been received, Pneu-C-13 should be given ≥1 year after the last dose of Pneu-P-23

Table 20: Pneu-P-23 reimmunization intervals for high risk individuals ≥2 years of age
• 2nd (one lifetime reimmunization) dose should be given ≥5 years after the 1st dose

Table 21: Rot-1 immunization series for infants <25 weeks of age
Recommended Intervals Minimum Intervals

1st dose between ages ≥2 months and <15 weeks 1st dose between ages ≥6 weeks and <15 weeks
2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose

• If an incomplete dose is administered for any reason (e.g., infant spits the vaccine) a replacement dose should NOT be administered.
• Vaccination should not be initiated in infants ≥15 weeks of age, as the safety of providing the first dose of Rot vaccine in older infants
is not known. If Rot is inadvertently administered at ≥15 weeks of age, the rest of the series should be completed with a minimum of
4 weeks between each dose and all doses should be administered at ≤25 weeks as per the product monograph, and no later than
32 weeks of age as per NACI.

Table 22: Tdap-IPV and/or Td and IPV primary immunization series for individuals ≥7 years of age
Recommended Intervals Minimum Intervals
1st dose 1st dose
2nd dose, 2 months after 1st dose 2nd dose, 4 weeks after 1st dose
3rd dose, 6-12 months after 2nd dose 3rd dose, 24 weeks after 2nd dose
Note: Refer to the Catch-up Schedules 2 and 3 for the use of Tdap-IPV and/or Td and IPV

Interrupted Vaccine Series

Table 23: Pneu-C-13 schedule for children <5 years of age who have not completed their series
Child’s Applies Number of Pneu-C-13 doses Number of Pneu-C-13 doses required to complete series
current age to received previously and recommended intervals
2nd dose, 2 months after 1st dose
1 dose (1st dose)
Healthy 3rd dose, 2 months after 2nd dose and at age ≥12 months
2 doses (1st and 2nd dose) 3rd dose, 2 months after 2nd dose and at age ≥12 months

2 to 6 months 2nd dose, 2 months after 1st dose

1 dose (1st dose) 3rd dose, 2 months after 2nd dose
High risk 4th dose, 2 months after 3rd dose and at age ≥12 months
3rd dose, 2 months after 2nd dose
2 doses (1st and 2nd dose) 4th dose, 2 months after 3rd dose and at age ≥12 months
2nd dose, 2 months after 1st dose
1 dose (1st dose)
7 to 11 months All 3rd dose, 2 months after 2nd dose and at age ≥12 months
2 doses (1st and 2nd dose) 3rd dose, 2 months after 2nd dose and at age ≥12 months
2nd dose, 2 months after 1st dose
1 dose (1st dose) at age <12 months
3rd dose, 2 months after 2nd dose
1 dose (1st dose) at age ≥12 months 2nd dose, 2 months after 1st dose
12 to 23 months All
1 dose (1st dose) at age <12 months and
3rd dose, 2 months after 2nd dose
1 dose (2nd dose) at age ≥12 months
2 or more doses at age <12 months 1 dose, 2 months after most recent dose

12
Table 23 cont.: Pneu-C-13 schedule for children <5 years of age who have not completed their series
Child’s Applies Number of Pneu-C-13 doses Number of Pneu-C-13 doses required to complete series
current age to received previously and recommended intervals

24 to 59 months All Any incomplete series 1 dose, 2 months after most recent dose
Note: See Table 17 to determine if the child has an interrupted schedule and requires additional doses in order to complete the
appropriate schedule for their current age

Table 24: Tdap-IPV, Td and IPV, and/or Td schedule for individuals ≥7 years of age who have not completed their series
Number of DTaP-IPV-[Hib] doses Continue with the following number of Tdap-IPV, Td and IPV and/or
received at age <7 years Individual’s current age
Td doses to complete series (recommended intervals)
1 dose of Tdap-IPV, 2 months after DTaP-IPV-[Hib] dose
7 to 17 years 1 dose of Tdap, 2 months after 1st Tdap-IPV dose
1 dose of Tdap-IPV, 6-12 months after Tdap dose
1 dose
1 dose of Tdap-IPV
≥18 years 1 dose of Td, 2 months after Tdap-IPV dose
1 dose of Td and IPV, 6-12 months after Td dose
1 dose of Tdap-IPV, 6-12 months after DTaP-IPV-[Hib] dose
7 to 17 years
1 dose of Tdap, 6-12 months after 1st Tdap-IPV dose
2 doses
1 dose of Tdap-IPV
≥18 years 1 dose of Td, 6-12 months after Tdap-IPV dose
3 doses ≥7 years 1 dose of Tdap-IPV, 6-12 months after DTaP-IPV-[Hib] dose
4 doses received at age <4 years ≥7 years 1 dose of Tdap-IPV
Note: DTaP-IPV-[Hib] indicates the use of either DTaP-IPV-Hib or DTaP-IPV depending on the age of the child

General notes:
• Eligible individuals include those who have an OHIP card, any other provincial or territorial health card from Canada, or any interim federal (Canadian)
health coverage, as well as children attending licensed child care settings and elementary and secondary schools.
• Eligibility for publicly funded vaccines may be extended in certain circumstances, such as case and contact management.
Contact your public health unit.
• Interruption of a vaccine series does not require restarting the series, regardless of the length of time that has elapsed since the last dose.
• When age ranges are specified, they are inclusive of the lower and upper age parameters, for example:
• “4-6 years” means from the 4th birthday to the day prior to the 7th birthday
• “6 months to 8 years” means from 6 months of age to the day prior to the 9th birthday
• A record of vaccines received at each visit must be provided free of charge. The Yellow Card is a permanent personal immunization record and should
be brought to all immunization appointments.
• In Ontario, up-to-date immunization records or valid exemptions are required for attendance at school, under the Immunization of School Pupils Act
(designated diseases include diphtheria, tetanus, polio, pertussis, meningococcal, measles, mumps, rubella, and varicella) and child care centres
under the Child Care and Early Years Act (consult your local public health unit).
• Refer to the Canadian Immunization Guide (phac-aspc.gc.ca/publicat/cig-gci/index-eng.php) for additional information.
• For vaccines not publicly funded or travel vaccines, refer to NACI (phac-aspc.gc.ca/naci-ccni/) and
CAMAT (phac-aspc.gc.ca/tmp-pmv/catmat-ccmtmv/index-eng.php) for indications and usage.
• Report adverse events following immunization (AEFI) to your local public health unit:
• Public health unit listing: health.gov.on.ca/English/public/contact/phu/phuloc_mn.html
• Ontario AEFI reporting form is available from Public Health Ontario: publichealthontario.ca/vaccinesafety

Visit Ontario.ca/vaccines to obtain the most current Publicly Funded Immunization Schedules for Ontario

13 Publicly Funded Immunization Schedules for Ontario – June 2022

 Public Health Units in Ontario

For more information or assistance regarding the Publicly

Funded Immunization Schedules for Ontario, please contact
your public health unit.
Visit health.gov.on.ca/en/common/system/services/phu/locations.aspx

Algoma 705-942-4646 1-866-892-0172

Brant County 519-753-4937

Chatham-Kent 519-352-7270

Durham 905-666-6241 1-800-841-2729

Eastern Ontario 613-933-1375 1-800-267-7120

Grey-Bruce 519-376-9420 1-800-263-3456

Haldimand-Norfolk 519-426-6170 905-318-6623

Haliburton, Kawartha, Pine Ridge District 1-866-888-4577

Halton 905-825-6000 1-866-442-5866

Hamilton 905-546-2489

Hastings Prince Edward 613-966-5500 1-800-267-2803

Huron Perth 1-888-221-2133

Kingston, Frontenac and Lennox & Addington 613-549-1232 1-800-267-7875

Lambton 519-383-8331 1-800-667-1839

14
 Leeds, Grenville and Lanark District 613-345-5685 1-800-660-5853

Middlesex-London 519-663-5317

Niagara 905-688-8248 1-888-505-6074

North Bay Parry Sound District 705-474-1400 1-800-563-2808

Northwestern 807-468-3147 1-800-830-5978

Ottawa 613-580-6744 1-866-426-8885

Peel 905-791-7800 1-888-919-7800

Peterborough 705-743-1000 1-877-743-0101

Porcupine 705-267-1181

Renfrew County and District 613-732-3629 1-800-267-1097

Simcoe Muskoka District 705-721-7520 1-877-721-7520

Southwestern 1-800-922-0096

Sudbury and Districts 705-522-9200 1-866-522-9200

Thunder Bay District 807-625-5900 1-888-294-6630

Timiskaming 705-647-4305 1-866-747-4305

Toronto 416-338-7600

Waterloo 519-575-4400

Wellington-Dufferin-Guelph 519-822-2715 1-800-265-7293

Windsor-Essex County 519-258-2146 1-800-265-5822

York 1-877-464-9675

15 Publicly Funded Immunization Schedules for Ontario – June 2022

Product No. 300270 ISBN: 978-1-4868-4530-9 (PDF) Revised June 2022 © Queen’s Printer for Ontario, 2022